ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) Article

Lassman, Andrew, Pugh, Stephanie, Wang, Tony et al. (2019). ACTR-21. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF DEPATUXIZUMAB MAFODOTIN (ABT-414) IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AMPLIFIED (AMP) NEWLY DIAGNOSED GLIOBLASTOMA (nGBM) . NEURO-ONCOLOGY, 21(Supplement_6), vi17-vi17. 10.1093/neuonc/noz175.064

cited authors

  • Lassman, Andrew; Pugh, Stephanie; Wang, Tony; Aldape, Kenneth; Gan, Hui; Preusser, Matthias; Vogelbaum, Michael; Sulman, Erik; Won, Minhee; Zhang, Peixin; Moazami, Golnaz; Macsai, Marian; Gilbert, Mark; Bain, Earle; Blot, Vincent; Ansell, Peter; Samanta, Suvajit; Kundu, Madan; Seidel, Clemens; De Vos, Filip; Hsu, Sigmund; Cardona, Andrés; Lombardi, Giuseppe; Bentsion, Dmitry; Peterson, Richard; Gedye, Craig; Lebrun-Frénay, Christine; Wick, Antje; Curran, Walter; Mehta, Minesh

authors

publication date

  • November 11, 2019

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Neurosciences

Digital Object Identifier (DOI)

publisher

  • Oxford University Press (OUP)

start page

  • vi17

end page

  • vi17

volume

  • 21

issue

  • Supplement_6